Previous Article | Next Article 
Journal of Virology, August 2001, p. 6800-6807, Vol. 75, No. 15
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.15.6800-6807.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Longer and Shorter Forms of Sendai Virus C Proteins Play
Different Roles in Modulating the Cellular Antiviral Response
Dominique
Garcin,1
Joseph
Curran,1
Masae
Itoh,2 and
Daniel
Kolakofsky1,*
Department of Genetics and Microbiology,
University of Geneva School of Medicine, CH1211 Geneva,
Switzerland,1 and Osaka Prefectural
Institute of Public Health, Higashinari, 537-0025 Osaka,
Japan2
Received 25 January 2001/Accepted 25 April 2001
 |
ABSTRACT |
The Sendai virus (SeV) C gene codes for a nested set of four C
proteins that carry out several functions, including the modulation of
viral RNA synthesis and countering of the cellular antiviral response.
Using mutant C genes (and in particular a C gene with a deletion of six
amino acids present only in the larger pair of C proteins) and
recombinant SeV carrying these mutant C genes, we find that the nested
set of C proteins carry out a nested set of functions. All of the C
proteins interdict interferon (IFN) signaling to IFN-stimulated genes
(ISGs) and prevent pY701-Stat1 formation. However, only the larger C
proteins can induce STAT1 instability, prevent IFN from inducing an
antiviral state, or prevent programmed cell death. Remarkably,
interdiction of IFN signaling to ISGs and the absence of pY701-Stat1
formation did not prevent IFN-
from inducing an anti-Vesicular
stomatitis virus (VSV) state. It is possible that IFN-
signaling to
induce an anti-VSV state can occur independently of the
well-established Jak/Stat/ISGF3 pathway and that it is this parallel
pathway that is targeted by the longer C proteins.
 |
INTRODUCTION |
Paramyxovirus P genes are remarkable
for the complexity of their genetic organization and expression. This
gene, named for the phosphoprotein that is an essential component of
the P/L viral RNA polymerase (vRNAP), contains additional open reading
frames (ORFs) that overlap the beginning and the middle of the P
protein ORF (the C and V ORFs, respectively) (Fig.
1). The C and V overlapping ORFs are
accessed by a variety of unusual mechanisms of ribosomal choice
(reviewed in references 9 and 31) and mRNA editing (39, 41), respectively. The overlapping ORFs are also
referred to as "accessory" genes (1) because in each
case there is at least one virus within the subfamily
Paramyxovirinae that does not contain (or express) the V or
C genes. For Sendai virus (SeV), a nested set of 2 longer C proteins
(C'ACG81 and CAUG114) and 2 shorter C proteins
(Y1AUG183 and Y2AUG201) are expressed (Fig. 1).
The two longer C proteins (along with the P protein) are initiated by
scanning ribosomes, whereas the two shorter C proteins are initiated by
a ribosomal shunt (31).

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 1.
ORF organization and expression of the SeV P gene. The
ORFs expressed as protein (P, C, V, and W) are shown as horizontal
boxes, drawn roughly to scale (above). Several domains of the P
protein, that which chaperones unassembled N protein (N°), its
tetramerization domain including the L protein binding site, and that
which binds to the N:RNA nucleocapsdid, are indicated. The
double-headed arrow shows the editing site (codon 317), where G
residues are added cotranscriptionally, to access the V and W ORFs. A
blowup of the 5' end of the mRNA is shown in the middle, and the five
ribosomal start sites in this region are indicated. The numbers refer
to the codon positions of the P and C ORFs. For the C ORF, the
AUG114-initiated C protein is the point of reference;
hence, the ACG81-initiated C' protein begins at position
11. All four C proteins terminate at codon 205. The 18-nucleotide
deletion that eliminates codons 13 to 18 of P and codons 10 to 15 of C
is shown, along with the N chaperone site of P. An alignment of
residues 9 to 19 of the C ORF with residues 273 to 300 of the
reovirus 3 protein (part of the dsRNA binding motif) is shown at the
bottom. The five basic residues essential for dsRNA binding are
indicated with asterisks.
|
|
The first property of the multifunctional C proteins noted was their
ability to modulate viral RNA (vRNA) synthesis. When vRNA synthesis is
reconstituted in vitro with purified N:RNA nucleocapsids and the
products of the P/C and L genes (expressed in transfected cell
extracts), specific ablation of C gene expression (or its replacement
with mutant CF170S genes) increases vRNAP specific activity
~8-fold (5). The longer C' or C proteins are equally
active in this respect, but the shorter Y proteins are inactive. The
inhibitory effects of C expression are promoter specific, in that
genomic promoters are considerably more sensitive to inhibition than
antigenomic promoters (1, 38). Remarkably, the negative
effects of C on vRNA synthesis are accompanied by an equivalent
increase in promoter fidelity, in that minigenomes with promoter
mutations (including those which destroy hexamer genome length) that
are lethal in the presence of C gene expression can replicate in its absence (34, 38).
C was initially thought to be a nonstructural virus protein, but it is
present in SeV particles at relatively low levels (ca. 40 molecules/genome [29, 43]). Its relative abundance
increases greatly during intracellular replication (C also increases
ca. 20-fold relative to the P and L proteins during the infection), and
the inhibitory effects of C are concentration dependent
(38). As C accumulates during infection, it is thought to
first shift vRNA synthesis from that of mRNAs and antigenomes toward
minus-strand genomes and then to shut down mRNA synthesis entirely in
preparation for assembling minus-strand genome nucleocapsids into
virions. The C protein(s) also plays a more direct role in virus
assembly, since progeny virions from infections missing all four C
proteins are poorly infectious and have altered morphology. The absence of C interactions with the M protein is thought to be responsible for
this defect in virus assembly (20, 28). Moreover, progeny virions from infections missing only the two larger C proteins have
less virion RNAP activity in vitro (unpublished), and there is a
significant delay in the onset of intracellular virus amplification during infection (30). In this respect, the essentially
nonstructural C proteins also act as an infectivity factor similar to
the human immunodeficiency virus type 1 vif protein, another accessory
(nonstructural) virus protein which counteracts the innate antiviral
activity of cells (36, 40).
The SeV CF170S mutation was uncovered as one of two
mutations (along with LE2050A) in a highly virulent strain
(SeVM; 50% lethal dose [LD50] of 40) that
became avirulent (SeVMVC; LD50 of >800,000) on
adaptation for growth in LLC-MK2 cells (21). Recombinant
SeV (rSeV) carrying the CMVC gene in an otherwise wild-type
strain Z background (rSeVZ-CMVC) is also
avirulent in mice, whereas rSeV strains carrying the CM
gene have not lost virulence (15). SeV C gene activity is
thus clearly required for virulence in mice. Although
rSeVZ-CMVC was avirulent, it grew normally in
the mouse respiratory tract at first, but virus was then quickly
cleared. The rapidity of this antiviral response in immunologically
naive mice, which mirrored that found in rSeV-[V-minus]
infections (23), suggested that some aspect of innate
immunity was involved (17). One such function has recently
been identified. Infection of interferon (IFN)-competent cells with SeV
or simian virus 5 (SV5) does not induce an antiviral state. These
paramyxovirus infections do not affect IFN-
/
secretion, but
somehow interfere with its receptor-mediated signaling since they also
prevent added IFN from inducing an antiviral state (12, 17,
19). For SeV, the C gene (Fig. 1) is clearly involved, since
viruses which carry the CF170S mutation, or those which do
not express any of the four C proteins, do not interfere with IFN
action (17, 28). Moreover, rSeV which cannot specifically
express CAUG114 (rSeVZ-[C-minus]) does not
prevent the IFN-induced antiviral state, even though this virus
normally expresses C'ACG81 and Y1, and overexpresses Y2.
SeVZ-[C-minus] is also avirulent in mice. The SeV
CAUG114 protein is thus specifically required for the full
range of IFN-mediated antiviral action and virulence in mice (18,
28, 30). Human parainfluenza virus type 1, like SeV, expresses
four C proteins, but most paramyxoviruses are thought to express a
single C protein, equivalent to SeV CAUG114. For the
rubulavirus SV5, which does not express a C protein, it is the V
protein that apparently functions to interdict IFN signaling (12,
13).
The SeV C proteins appear to be multifunctional proteins, playing roles
in such diverse processes as modulating vRNA synthesis, interdicting
IFN action, delaying CPE (antiapoptosis), and ensuring proper virion
assembly and infectivity. We describe here experiments designed to
elucidate the role of the various C proteins in some of these multiple functions.
 |
MATERIALS AND METHODS |
Cells and viruses.
Murine BF cells (cloned from a primary
cell culture of a BALB/c mouse embryo) and mouse embryo fibroblasts
(MEFs) (44) were grown as monolayers in Dulbecco modified
Eagle medium supplemented with 10% fetal bovine serum. The generation
of rSeV expressing alternate C (and P) proteins has been described
elsewhere (10, 14, 15, 30). All SeV stocks were grown in
the allantoic cavity of 10-day-old embryonated chicken eggs. Virus
present in the allantoic fluids was analyzed by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Coomassie
blue staining after virus pelleting. Virus titers were determined by
plaque formation on LLC-MK2 cells. The vesicular stomatitis virus (VSV)
stock (Mudd-Summers) was grown in BHK cells. Virus released into the
culture medium was clarified by centrifugation to remove cell debris,
and the titer was determined by plaque formation on LLC-MK2 cells.
Plasmid DNAs.
The IFN-
/
responsive reporter plasmid,
p(9-27)4tk(
39)lucter (24, 25), referred to
here as pISRE(f)luc, contains four tandem repeats of the IFN-inducible
gene 9-27 ISRE fused to the firefly luciferase gene. pTK-r.luc., used
as a transfection standard, contains the herpes simplex virus TK
promoter region upstream of the Renilla luciferase gene (Promega).
Transient transfections.
Monolayers of BF cells in
5.5-cm-diameter plates (at 50% confluence) were transfected with a
total of 2 µg of DNA and 6 µl of Effectene (Qiagen) according to
the manufacturer's instructions. At 24 h posttransfection, the
cells were (or were not) infected with 20 PFU of SeV per cell and
treated with 1,000 IU of recombinant IFN-
2/
1 (42)
per ml at 48 h posttransfection. At 4 to 12 h after
IFN treatment, cells were harvested and assayed for firefly and
Renilla luciferase activity (dual-luciferase reporter assay system; Promega). Relative expression levels were calculated by dividing the firefly luciferase values by those of the
Renilla luciferase.
Immunoblotting.
Proteins were separated by SDS-PAGE and
transferred to Immunobilon-P membranes by semidry transfer. The primary
antibodies used included a rabbit polyclonal antiserum to VSV P protein
(provided by J. Perrault and D. Summers), a rabbit polyclonal antiserum to SeV P protein isolated from an SDS gel (anti-PSDS; L. Roux, Geneva, Switzerland), a mouse monoclonal antibody to SeV N (N877
[33]), a rabbit polyclonal antiserum to SeV C protein (provided by Y. Nagai, Tokyo, Japan), a mouse monoclonal antibody to
Stat1 C terminus (Transduction Laboratories S21120), a rabbit polyclonal antiserum to Phospho-Stat (Y701) (Upstate Biotechnology 06-657), and a rabbit polyclonal antiserum to actin (provided by G. Gabbiani, Geneva, Switzerland). The secondary antibodies used were
alkaline phosphatase-conjugated goat antibodies specific for either
rabbit or mouse immunoglobulin G (Bio-Rad). The immobilized proteins
were detected by light-enhanced chemiluminescence (Bio-Rad).
Measurement of phosphatidylserine exposure by Annexin-V
fluorescence.
HeLa cells from 5.5-cm petri dishes were harvested
and analyzed by flow cytometry using Annexin-V-Alexa 568 (Roche) and
BOBO-1 (Molecular Probes) at 48 h postinfection, according to the
manufacturer's instructions.
In vitro RNA synthesis.
RNA synthesis in vitro was performed
essentially as described by Curran et al. (6) with the
modifications outlined in Curran (8). N:RNA nondefective
templates were isolated from infected egg allantoic fluid (strain Z) by
banding twice on 20 to 40% CsCl gradients. Templates were resuspended
at a concentration of ca. 250 ng/µl in TE (10 mM Tris [pH 7.4],
1 mM EDTA) containing 1 mM dithiothreitol-10% glycerol and
stored at
80°C. A549 cells (5-cm-diameter petri dish) were
transfected with 5 µg of pGEM-P/C (or mutant P/C clone) and 1 µg of
pGEM-L. In vitro RNA synthesis was generally carried out in 100-µl
reaction mixtures containing 5 µl of the template, 90 µl of
vaccinia virus-T7 (VV-T7)-infected A549 cell extract, 30 µCi of
[32P]GTP, and 20 µg of actinomycin D per ml at
30°C for 3 h. After the reaction, 500 µl of lysis buffer (150 mM NaCl, 50 mM Tris [pH 7.4], 10 mM EDTA, 0.6% NP-40) was added, and
the RNA was recovered by pelleting through 5.7 M CsCl. Products were
analyzed directly on 1.5% agarose-HCHO gels.
 |
RESULTS |
C gene inhibition of vRNA synthesis and rSeV recovery are separate
events.
The coexpression of either of the two larger C proteins
during SeV vRNAP complex formation in transfected cells strongly
reduces the specific activity of the P/L vRNAP (P/Cwt
versus P/Cstop, Fig. 2), but
the coexpression of Y1 and/or Y2 is not inhibitory (5).
This capacity of the longer C proteins to inhibit vRNA synthesis thus
appears to depend on the 23 NH2-terminal residues (or
C1-23) of CAUG114 (Fig. 1). Moreover,
virtually the entire C ORF upstream of Y1AUG183 can be
aligned with a small portion of the double-stranded RNA (dsRNA) binding
domain of the reovirus
3 protein (
3 also functions in preventing
the host cell's innate antiviral response, presumably by sequestering
dsRNA and preventing PKR activation [11]). We were
therefore interested in further defining the function of the
C1-23 domain (the 23 NH2-terminal residues of
CAUG114) and, if possible, within a rSeV so that its
properties in cellular and animal infections could be determined.

View larger version (76K):
[in this window]
[in a new window]
|
FIG. 2.
C protein expression inhibits SeV mRNA synthesis in
transfected cell extracts. Viral mRNA synthesis was carried out with
purified N:RNA nucleocapsids and cytoplasmic extracts of vTF7-3
infected A549 cells that had been transfected with pGEM-L and various
pGEM-P/C plasmids (as indicated above), in the presence of actinomycin
D and [ -32P]GTP (see Materials and
Methods). P/Cstop contains a stop codon just downstream of
AUG201 (Y2) and does not express any of the C proteins;
none, control (no pGEM-P/C). The products of the reaction were purified
by Trizol extraction and separated on a 1.5% formaldehyde-agarose gel.
The N and P mRNA bands were quantified in a PhosphorImager, and their
relative intensities are shown below.
|
|
It has not yet been possible to separate the P and C gene ORFs into
individual transcription units in rSeV. rSeV with deletions within
C1-23 of the C ORF will also carry the corresponding
deletions in the P ORF, and both deletions could potentially affect
rSeV viability. We had originally introduced a series of eight short
deletions within the first 69 codons of the SeV P ORF (to locate a P
protein domain (N°, Fig. 1) that chaperones unassembled N protein
during the nascent-chain assembly step of genome replication
[7]). Three of these deletions, C
2-8/P
5-11,
C
9-15/P
12-18, and C
16-22/P
19-25, were located within
C1-23. In spite of the importance of the C gene in many
aspects of SeV replication, its coexpression from the pGEM-P/C support
plasmid during rSeV recovery from DNA in the VV-infected and
plasmid-transfected (VV-T7) cell system is highly deleterious and needs
to be suppressed (1, 14, 15). Our VV-T7 recovery system
can also be highly recombinogenic, and rSeV carrying P/C gene mutations
which lead to a selective disadvantage vs rSeVwt are
generally lost in the recovery unless the pGEM-P/C support plasmid also
carries the same mutation (see below). However, when these three
deleted pGEM-P/C support plasmids were examined for their ability to
rescue rSeVwt from DNA, we were surprised to find that,
whereas C
2-8 and C
16-22 prevented rSeV recovery as had
Cwt, C
9-15 had lost this property (data not shown).
pGEM-P
12-18/C
9-15 could then be used (if necessary) to rescue
rSeV without inactivating its C protein expression.
We had originally assumed that the capacities of the C proteins to
inhibit rSeV recovery and vRNA synthesis were related, because C is a
powerful inhibitor of minigenome replication in the VV-T7 system and
CF170S genes were null mutants for both properties
(1, 38). We therefore expected that at least one of these
three deletions (including C
9-15) would further identify a domain
required for CAUG114 to inhibit vRNA synthesis. However,
when C
2-8, C
9-15, and C
16-22 were examined for their ability
to inhibit RNA synthesis, we were further surprised to find that all
were wild type in this respect (Fig. 2 and data not shown; see
Discussion). Thus, although the properties of inhibiting vRNA synthesis
and rSeV recovery are linked by their requirement for F170, they are
also separate events (see Fig. 7). Moreover, we have uncovered other
mutant C genes that have precisely this phenotype, i.e., their products
inhibit vRNA synthesis normally but no longer prevent rSeV recovery
(e.g., CG162A [data not shown]).
rSeV-[C
10-15/P
13-18].
A rSeV containing a
21-nucleotide-deleted genome (encompassing C protein residues
9Leu-Lys-Leu-Arg-Gly-Arg-Arg15) is not expected
to be viable (2). We therefore restricted ourselves to the
six-amino-acid aa deletion of C
10-15 (and P
13-18), since
C
10-15 also inhibits vRNA synthesis as had Cwt (Fig. 2,
lanes 1, 4, and 5). Recovery of rSeV carrying this deletion was first
attempted with our pGEM-P/Cstop support plasmid, but only
rSeVwt was recovered under these conditions (presumably as
the result of recombination between pGEM-P/Cstop and the
full-length viral cDNA in the VV-T7 system).
rSeV-[C
10-15/P
13-18] was only recovered when the P gene
support plasmid contained the same deletion. Although
rSeV-[C
10-15/P
13-18] is viable and produces normal
plaques, this virus clearly cannot compete against the small amounts of
SeVwt that are generated by recombination during virus
recovery with pGEM-P/Cwt.
rSeV-[P
13-18/C
10-15] is also avirulent in mice (Table
1). It is possible that the P protein
deletion also contributes to the reduced fitness of
rSeV-[C
10-15/P
13-18], even though the P
13-18 protein
is wild type in all aspects of vRNA synthesis that can be reproduced in
transfected cells and extracts (Fig. 2 and data not shown).
rSeV-[P
13-18/C
10-15] grows as well as rSeVwt in MEFs (see Fig. 6, lower panel) and HeLa and BHK
cells (data not shown). However, unlike rSeVwt
rSeV-[P
13-18/C
10-15] is partially sensitive to IFN
treatment (see Fig. 6 and below).
Characterization of rSeV-C
10-15/P
13-18, and IFN
signaling through the Jak/Stat/ISGF3 pathway.
IFN-
/
molecules bind to a common IFN-
/
receptor, and this initiates a
series of tyrosine phosphorylation events, including activation of the
Janus tyrosine kinases Jak1 and Tyk2, which are found associated with
the IFN-
/
receptor. Activation of Jak1 and Tyk2 results in the
tyrosine phosphorylation of Stat1 and Stat2 and in the formation of
IFN-stimulated gene factor 3 (ISGF3) composed of Stat1, Stat2, and p48.
Nuclear translocation of ISGF3 and its subsequent binding to
IFN-stimulated response elements (ISRE) leads to the activation of a
variety of IFN-stimulated genes (ISG) which control the biological
activity of IFN-
/
(reviewed in reference 37).
As shown previously (17), wild-type SeVM
infection of IFN-competent BF cells that have been transfected with
pISRE-luc (a luciferase reporter plasmid containing a basal promoter
with a tandemized ISRE) (24, 25) induces only low levels
of luciferase (Fig. 3). SeVM
infection, moreover, also inhibits IFN signaling to pISRE-luc (+IFN,
Fig. 3). Infection with SeVMVC, in contrast, induces high
levels of luciferase even without IFN treatment, since
SeVMVC infection induces strong IFN production without
being able to interfere with its action (17). Infection
with rSeV-[C
10-15/P
13-18] is almost as efficient as
wild-type SeVM in suppressing IFN-induced luciferase
activity (Fig. 3). Identical results were obtained by expressing
C
10-15 independent of SeV infection in a transfected-cell assay
(data not shown). These results are consistent with the previous
demonstration that the Y1 and Y2 proteins are as effective as the
longer C proteins at interdicting IFN signaling to pISRE-luc, either
when expressed independent of, or within an rSeV infection (17,
18).

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 3.
IFN signaling to pISRE-luciferase. BF cells were
transfected with pISRE-(f)luc and pTK-(r)luc and then infected (or not)
with 20 PFU of various rSeV types per cell as indicated on the
x axis. Some of the cultures were treated with 1,000 U of
IFN- per ml at 48 h posttransfection. All of the cultures were
harvested at 60 h, and the relative levels of Renilla
and firefly luciferase activities were determined. A timeline of the
experiment is shown at the top of the figure.
|
|
IFN-
signaling through the Jak/Stat pathway depends on the critical
phosphorylation of Y701 of Stat1 (37) and SeV infection of
HeLa cells prevents IFN-
-induced formation of pY701-Stat1 (19). To determine whether this block was due to the
action of the C gene, we infected BF cells with SeV carrying either the wild-type CM, mutant CMVC (F170S), or C
10-15
genes. At 24 h postinfection (hpi), the cultures were treated (or
not) with IFN and harvested 40 min later, and the relative levels of
pY701-Stat1 present in whole-cell extracts were determined by
immunoblotting. As shown in Fig. 4,
24 h of SeVMVC infection induces almost as much
pY701-Stat1 as a 40-min treatment of mock-infected cells with 1,000 U
of IFN-
. SeVM infection, in contrast, induces only
barely detectable levels of pY701-Stat1 and, furthermore, prevents IFN
treatment from inducing pY701-Stat1. Thus, the SeV block on IFN-induced
pY701-Stat1 formation is indeed due to the action of its C gene, and
the interdiction of IFN signaling to pISRE-luc can be explained, at
least in large part, by its action at or upstream of pY701-Stat1
formation in this signaling pathway. rSeV-[C
10-15]
infection was found to be as effective as that of wild-type
rSeVM in preventing IFN-induced pY701-Stat1 formation.
Moreover, identical results were obtained when pS727-Stat1 formation
was examined (data not shown). Note that the two M strain viruses
equally express C' and C, but undetectable amounts of Y1 or Y2, the
ribosomal shunt appears to be inoperative here (Fig. 4). Thus, the
differences between SeVM and SeVMVC infections
are not due to differences in the type and amount of C proteins.
rSeV-C
10-15 (in the Z strain background), on the other hand,
expresses significant amounts of all four C proteins, as did
SeVZ-wt. However, the total amount of C proteins
accumulated during these three SeV infections is roughly similar. Thus,
interdiction of IFN signaling to pISRE-luc, including pY701-Stat1 and
pS727-Stat1 formation, does not appear to require C1-23,
but only a functional Y protein.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 4.
IFN induced formation of pY701-Stat1 and the antiviral
(VSV) state. (A) BF cells were infected (or not) with 20 PFU of the
various rSeVs per cell as indicated above and treated (or not) with
1,000 U of IFN- per ml at 24 hpi, as indicated. Total cell extracts
were prepared 40 min later, separated by SDS-PAGE, and immunoblotted
with anti-Stat1 (top), anti-pY701-Stat1 and anti-actin (middle), and
anti-C (bottom). A timeline of the experiment is shown at the top of
the figure. (B) BF cells were infected (or not) with 20 PFU of the
various rSeVs per cell as indicated above and treated (or not) with
1,000 U of IFN- per ml at time zero, as indicated. All of the
cultures were infected with 50 PFU of VSV per cell at 24 hpi. The cells
were harvested at 28 hpi, and the levels of VSV P protein in
cytoplasmic extracts were determined by immunoblotting. An anti-actin
antibody was included as a loading control. A timeline of the
experiment is shown above.
|
|
Remarkably, even though rSeV-[C
10-15] prevents IFN-induced
pY701-Stat1 formation and activation of pISRE-luc, this virus is
largely unable to prevent the IFN-induced anti-VSV state. As shown in
Fig. 4B, BF cells are refractory to VSV replication upon 24 h of
IFN treatment, but VSV replicates well in these cells if they are
simultaneously infected with SeVM, as was previously found
(17). However, if these IFN-treated cells are
simultaneously infected with rSeV-[C
10-15], VSV
replication is still largely restricted.
Cytopathic effects of rSeV.
SeVM infections induce
programmed cell death (PCD) poorly either in LLC-MK2 cells or the mouse
respiratory tract, whereas SeVMVC infections are highly
cytopathic in both cases (21). Although SeVM
and SeVMVC differ by two amino acids substitutions
(CF170S and LE2050A [22]),
further work with rSeVZ-CM and
rSeVZ-CMVC has indicated that this difference
in the cellular response to the infection is, at least in part, another
property of the C gene (data not shown).
We have examined a panel of rSeV mutants to determine whether their
infections are highly cytopathic (like SeVMVC) or
relatively noncytopathic (like SeVM), by examining Annexin
V staining (apoptosis) of rSeV-infected HeLa cells, one
indicator of PCD (Fig. 5). Infection with
rSeV that cannot specifically express either of the longer C proteins individually (rSeV-[C'-minus] or rSeV-[C-minus])
are as poorly cytopathic as SeVM, whereas
rSeV-[C'/C-minus], the double mutant, is as cytopathic as SeVMVC. Thus, the two longer C proteins (but not Y1 and
Y2) appear to actively suppress virus-induced apoptosis. This property
specifically requires C10-15, since rSeV-C
10-15
is also highly apoptogenic. The NH2-terminal extensions of
the C protein and, in particular, the highly basic residues
C10-15, are thus critical in preventing or delaying at
least one aspect of virus-induced cytopathic effects. In contrast,
"copyback" rSeV that express wild-type C genes but that do not
contain C-sensitive promoters (GP42 and GP48) are even less cytopathic
than SeVM, as has been previously noted (16).

View larger version (44K):
[in this window]
[in a new window]
|
FIG. 5.
SeV-induced programmed cell death. HeLa cells were
infected (or not) with 20 PFU of the various SeVs per ml as indicated
below. At 48 hpi, the cells were stained with Annexin V and examined by
fluorescence-activated cell sorting. The average percentage of cells
considered apoptotic (from duplicate infections) is shown.
|
|
Antiviral state.
We have recently described a 3T3 MEF cell
line which appears to be in an antiviral (VSV) state without IFN
treatment, and this antiviral (VSV) state is associated with high basal
Stat1 levels (18). When these MEFs are infected with SeV
containing wild-type C genes (e.g., rSeVZ-CM,
listed as "M" in lanes 3 and 4 in Fig.
6), Stat1 levels are strongly decreased,
and VSV can now replicate in these cells. Moreover, exogenous IFN
treatment of the cells does not decrease the level of
rSeVZ-CM replication (lower panel, lane 4).
When these MEFs are infected with rSeV-[C
10-15], they
behave like those infected with rSeVZ-CMVC,
namely, the Stat1 levels are not decreased and VSV replication continues to be largely restricted. Moreover, intracellular replication of rSeV-[C
10-15] is clearly reduced by IFN treatment, like
that of rSeVZ-CMVC (lower panel). These results
are similar to those obtained with rSeVZ-[C'/C-minus],
whose infection is also unable to prevent the IFN-induced anti-VSV
state (17). The entire CAUG114 protein and, in
particular, the highly basic residues C10-15 are thus
required to effectively counter the IFN-induced antiviral (VSV) state.

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 6.
Effect of SeV infection on Stat1 levels and induction of
an antiviral state. Parallel cultures of NIH 3T3 MEFs were infected
with either SeVZ-CM (M),
SeVZ-CMVC (MVC), or SeV-[C 10-15] or were
not infected and then concomitantly treated (or not) with 1,000 U of
IFN- , per ml, as indicated. The cultures were superinfected with VSV
(50 PFU/cell) at 50 h post-SeV infection and harvested at 55 hpi.
The relative levels of the cellular Stat1 and VSV P proteins were
determined by immunoblotting (upper panel). An anti-actin antibody was
included to control for the amount of cellular material loaded onto
each lane. Equal samples of the various cell extracts were used to
determine the relative levels of the SeV N and P proteins present by
immunoblotting (lower panel).
|
|
 |
DISCUSSION |
The SeV C proteins consist of a nested set of two longer (C' and
C) and two shorter (Y1 and Y2) proteins, which carry out multiple
functions. We have investigated three (or more) of these functions,
including (i) inhibiting or modulating vRNA synthesis, (ii)
interdicting IFN signaling through the Jak/Stat/ISGF3 pathway, and
(iii) a group of events that may be linked, namely, reducing Stat1
levels, preventing the IFN-induced antiviral (VSV) state, preventing
programmed cell death (including apoptosis), and the enigmatic property
of preventing rSeV recovery in the VV-T7 system. Our results indicate
that the nested set of C proteins carry out a nested set of these
functions, affecting both viral replication and the cellular antiviral
response (Fig. 7). Because of these effects, rSeV strains which express only the shorter Y1 and Y2 proteins
are highly debilitated, and those which do not express any of the four
C proteins are even further debilitated (they are at the limit of rSeV
recovery [28, 30]). Here, we report the properties of
rSeV containing a deletion of a short, but notable, region of the C
(and overlapping P) gene. rSeV-[C
10-15] is also highly
debilitated (avirulent in mice and outgrown by rSeVwt in
mixed infections), underscoring the importance of the first 23 residues
of CAUG114 in virus replication. rSeV that cannot express
the V or W proteins (two other accessory proteins of the P gene; Fig.
1), in contrast, replicates well in cell culture (10, 23).

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 7.
Schematic representation the SeV C proteins and their
activities. The longer C proteins are shown as being composed of the Y
protein module (large box) in which F170 is critical for all
activities, plus an NH2-terminal extension of either 23 (CAUG114) or 34 (C'ACG81) residues. The
deletions within C1-23 examined are indicated. The various
activities of the C proteins are listed below in three groups
distinguished by the phenotypes of the various mutant C genes examined.
The numbers 1 to 23 and 10 to 15 refer to these residues within
CAUG114. For further explanation, see the text. The values
for residues 1 to 23 were determined from the activity of the Y1
protein.
|
|
The shorter Y proteins appear to be both necessary and sufficient to
interdict IFN signaling to pISRE-luc (Fig. 3) or to prevent the
critical formation of pY701-Stat1 required for this IFN signaling (Fig.
4). The interdiction of IFN signaling through the Jak/Stat/ISGF3 pathway is therefore one function that can be carried out by all of the
C proteins (18). Since SeV infection prevents IFN-induced pY701-Stat1 formation within 2 hpi (26), this block on IFN
signaling is a very early effect of the C gene, which occurs when very
little of this essentially nonstructural protein is present
intracellularly. Large amounts of the C proteins accumulate during
infection, and these gene products also appear to be responsible for
the dramatic turnover of Stat1 that occurs upon infection of some cells
(Fig. 6). This effect on Stat1 stability, however, requires
C10-15, and it is therefore unlikely to be due to the same
C interaction that suppresses pY701-Stat1 formation (Fig. 7).
The C proteins also inhibit vRNA synthesis in a promoter-specific
manner but, in contrast to their interdiction of the Jak/Stat/ISGF3 pathway, the shorter Y proteins are unable to carry out this task. This
suggested that a domain within C1-23 was specifically
required for this inhibition, but we were unable to map such a domain
by serial deletions. The role of C1-23 in the inhibition
of viral RNA synthesis is thus unclear. C1-23, however, is
likely to play a specific role in SeV infection, because several
properties of this gene (its ability to reduce Stat1 levels, to prevent
the SeV infection from inducing a cellular antiviral state, or PCD, or
to prevent rSeV recovery in the VV-T7 system [Fig. 7]) are all
inactivated by the deletion of C10-15. Leaving aside the
enigmatic rSeV recovery phenomenon, the remaining three properties may
very well be linked. The IFN-induced antiviral state and PCD are
complex cellular responses that integrate signals from different
pathways, and Stat1 is prominent in both cellular responses.
Eliminating Stat1 could act to prevent PCD (4, 27, 35),
and there may be elements of IFN action that require basal levels of
Stat1, independent of their phosphorylation status (3). If
so, these three properties could be due to a common interaction of
CAUG114 (but not Y1 or Y2) and Stat1, along with other
cellular components.
The Y proteins appear to be as active as the longer C proteins in
interdicting IFN signaling through the Jak/Stat pathway in both
transfected cells and rSeV-infected cells (17,
18). We were therefore surprised to find that Y1 or Y2
expression alone, in the context of rSeV-[C'/C-minus] or
rSeV-[C
10-15] infection, was unable to prevent IFN from
inducing an effective anti-VSV state. We had assumed that the
interdiction of this now well-established IFN signaling pathway would
have been sufficient to prevent IFN action, but this seems not to be so
in IFN-competent BF cells and MEFs. The IFN-induced antiviral state is
known to be remarkably complex (37), and interdicting IFN
signaling to ISRE-promoted ISGs is clearly not the same as preventing
IFN from inducing an anti-VSV state. There is increasing evidence that
while Jak/Stat pathways are essential, they are not necessarily
sufficient for all aspects of the IFN-induced response. There may be
another parallel pathway through which IFN acts to induce an antiviral (VSV) state, and which could require basal levels of Stat1 (independent of their phosphorylation). For example, Novick et al. (32)
have recently described monoclonal antibodies to the IFNAR2 chain that neutralize IFN-
action but that neither prevent IFN-
from binding to its receptor, Jak/Stat tyrosine phosphorylation, or ISGF3 complex formation. It is perhaps this pathway that is targeted by the longer C proteins.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Genetics and Microbiology, University of Geneva School of Medicine,
CMU, 9 Ave. de Champel, CH1211 Geneva, Switzerland. Phone:
41-22-702-56-57. Fax: 41-22-702-57-02. E-mail:
Daniel.Kolakofsky{at}Medecine.unige.ch.
 |
REFERENCES |
| 1.
|
Cadd, T.,
D. Garcin,
C. Tapparel,
M. Itoh,
M. Homma,
L. Roux,
J. Curran, and D. Kolakofsky.
1996.
The Sendai paramyxovirus accessory C proteins inhibit viral genome amplification in a promoter-specific fashion.
J. Virol.
70:5067-5074[Abstract/Free Full Text].
|
| 2.
|
Calain, P., and L. Roux.
1993.
The rule of six: a basic feature for efficient replication of Sendai virus defective interfering RNA.
J. Virol.
67:4822-4830[Abstract/Free Full Text].
|
| 3.
|
Chatterjee-Kishore, M.,
K. L. Wright,
J. P. Ting, and G. R. Stark.
2000.
How Stat1 mediates constitutive gene expression: a complex of unphosphorylated Stat1 and IRF1 supports transcription of the LMP2 gene.
EMBO J.
19:4111-4122[CrossRef][Medline].
|
| 4.
|
Chin, Y. E.,
M. Kitagawa,
K. Kuida,
R. A. Flavell, and X.-Y. Fu.
1997.
Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis.
Mol. Cell. Biol.
17:5328-5337[Abstract].
|
| 5.
|
Curran, J.,
J.-B. Marq, and D. Kolakofsky.
1992.
The Sendai virus nonstructural C proteins specifically inhibit viral mRNA synthesis.
Virology
189:647-656[CrossRef][Medline].
|
| 6.
|
Curran, J.,
T. Pelet, and D. Kolakofsky.
1994.
An acidic activation-like domain of the Sendai virus P protein is required for RNA synthesis and encapsidation.
Virology
202:875-884[CrossRef][Medline].
|
| 7.
|
Curran, J.,
J.-B. Marq, and D. Kolakofsky.
1995.
An N-terminal domain of the Sendai virus P protein acts as a chaperone for NP protein during the nascent chain assembly step of genome replication.
J. Virol.
69:849-855[Abstract].
|
| 8.
|
Curran, J.
1996.
Reexamination of the Sendai virus P protein domains required for RNA synthesis: a possible supplemental role for the P protein.
Virology
221:130-140[CrossRef][Medline].
|
| 9.
|
Curran, J.,
P. Latorre, and D. Kolakofsky.
1998.
Translational gymnastics on the Sendai virus P/C mRNA.
Semin. Virol.
8:351-357[CrossRef].
|
| 10.
|
Delenda, C.,
S. Hausmann,
D. Garcin, and D. Kolakofsky.
1997.
Normal cellular replication of Sendai without the trans-frame, nonstructural V protein.
Virology
228:55-62[CrossRef][Medline].
|
| 11.
|
Denzler, K. L., and B. L. Jacobs.
1994.
Site-directed mutagenic analysis of reovirus sigma 3 protein binding to dsRNA.
Virology
204:190-199[CrossRef][Medline].
|
| 12.
|
Didcock, L.,
D. F. Young,
S. Goodbourn, and R. E. Randall.
1999.
The V protein of simian virus 5 inhibits interferon signaling by targeting STAT1 for proteasome-mediated degradation.
J. Virol.
73:9928-9933[Abstract/Free Full Text].
|
| 13.
|
Didcock, L.,
D. F. Young,
S. Goodbourn, and R. E. Randall.
1999.
Sendai virus and simian virus 5 block activation of interferon-responsive genes: Importance for virus pathogenesis.
J. Virol.
73:3125-3133[Abstract/Free Full Text].
|
| 14.
|
Garcin, D.,
T. Pelet,
P. Calain,
L. Roux,
J. Curran, and D. Kolakofsky.
1995.
A highly recombinogenic system for the recovery of infectious Sendai paramyxovirus from cDNA: generation of a novel copy-back nondefective interfering virus.
EMBO J.
14:6087-6094[Medline].
|
| 15.
|
Garcin, D.,
M. Itoh, and D. Kolakofsky.
1997.
A point mutation in the Sendai virus accessory C proteins attenuates virulence for mice, but not virus growth in cell culture.
Virology
238:424-431[CrossRef][Medline].
|
| 16.
|
Garcin, D.,
G. Taylor,
K. Tanebayashi,
R. Compans, and D. Kolakofsky.
1998.
The short Sendai virus leader region controls induction of programmed cell death.
Virology
243:340-353[CrossRef][Medline].
|
| 17.
|
Garcin, D.,
P. Latorre, and D. Kolakofsky.
1999.
Sendai virus C proteins counteract the interferon-mediated induction of an antiviral state.
J. Virol.
73:6559-6565[Abstract/Free Full Text].
|
| 18.
|
Garcin, D.,
J. Curran, and D. Kolakofsky.
2000.
Sendai virus C proteins must interact directly with cellular components to interfere with interferon action.
J. Virol.
74:8823-8830[Abstract/Free Full Text].
|
| 19.
|
Gotoh, B.,
K. Takeuchi,
T. Komatsu,
J. Yokoo,
Y. Kimura,
A. Kurotani,
A. Kato, and Y. Nagai.
1999.
Knockout of the Sendai virus C gene eliminates the viral ability to prevent the interferon-alpha/beta-mediated responses.
FEBS Lett.
459:205-210[CrossRef][Medline].
|
| 20.
|
Hasan, M. K.,
A. Kato,
M. Muranaka,
R. Yamaguchi,
Y. Sakai,
I. Hatano,
M. Tashiro, and Y. Nagai.
2000.
Versatility of the accessory C proteins of Sendai virus: contribution to virus assembly as an additional role.
J. Virol.
74:5619-5628[Abstract/Free Full Text].
|
| 21.
|
Itoh, M.,
H. Hotta, and M. Homma.
1998.
Increased induction of apoptosis by a Sendai virus mutant is associated with attenuation of mouse pathogenicity.
J. Virol.
72:2927-2934[Abstract/Free Full Text].
|
| 22.
|
Itoh, M.,
Y. Isegawa,
H. Hotta, and M. Homma.
1997.
Isolation of an avirulent mutant of Sendai virus with two amino acid mutations from a highly virulent field strain through adaptation to LLC-MK2 cells.
J. Gen. Virol.
78:3207-3215[Abstract].
|
| 23.
|
Kato, A.,
K. Kiyotani,
Y. Sakai,
T. Yoshida, and Y. Nagai.
1997.
The paramyxovirus Sendai virus V protein encodes a luxury function required for viral pathogenesis.
EMBO J.
16:678-587.
|
| 24.
|
King, P., and S. Goodbourn.
1994.
The -interferon promoter responds to priming through multiple independent regulatory elements.
J. Biol. Chem.
269:30609-30615[Abstract/Free Full Text].
|
| 25.
|
King, P., and S. Goodbourn.
1998.
STAT1 is inactivated by a caspase.
J. Biol. Chem.
273:8699-8704[Abstract/Free Full Text].
|
| 26.
|
Komatsu, T.,
K. Takeuchi,
J. Yokoo,
Y. Tanaka, and B. Gotoh.
2000.
Sendai virus blocks alpha interferon signaling to signal transducers and activators of transcription.
J. Virol.
74:2477-2480[Abstract/Free Full Text].
|
| 27.
|
Kumar, A.,
M. Commane,
T. W. Flickinger,
C. M. Horvath, and G. R. Stark.
1997.
Defective TNF -induced apoptosis in STAT1-null cells due to low constitutive levels of caspases.
Science
278:1630-1632[Abstract/Free Full Text].
|
| 28.
|
Kurotani, A.,
K. Kiyotani,
A. Kato,
T. Shioda,
Y. Sakai,
K. Mizumoto,
T. Yoshida, and Y. Nagai.
1998.
Sendai virus C proteins are categorically nonessential gene products but silencing their expression severely impairs viral replication and pathogenesis.
Genes Cells
3:111-124[Abstract].
|
| 29.
|
Lamb, R. A.,
B. W. Mahy, and P. W. Choppin.
1996.
The synthesis of Sendai virus polypeptides in infected cells.
Virology
69:116-131.
|
| 30.
|
Latorre, P.,
T. Cadd,
M. Itoh,
J. Curran, and D. Kolakofsky.
1998.
The various Sendai virus C proteins are not functionally equivalent and exert both positive and negative effects on viral RNA accumulation during the course of infection.
J. Virol.
72:5984-5993[Abstract/Free Full Text].
|
| 31.
|
Latorre, P.,
D. Kolakofsky, and J. Curran.
1998.
Sendai virus Y proteins are initiated by a ribosomal shunt.
Mol. Cell. Biol.
18:5021-5031[Abstract/Free Full Text].
|
| 32.
|
Novick, D.,
R. R. Nabioullin,
W. Ragsdale,
S. McKenna,
W. Weiser,
L. Garone,
C. Burkins,
S. H. Kim,
M. Rubinstein,
M. A. Tepper, and A. R. Arulanandam.
2000.
The neutralization of type I IFN biologic actions by anti-IFNAR-2 monoclonal antibodies is not entirely due to inhibition of jak-stat tyrosine phosphorylation.
J. Interferon Cytokine Res.
20:971-982[CrossRef][Medline].
|
| 33.
|
Orvell, C., and M. Grandien.
1982.
The effects of monoclonal antibodies on biological activities of structural proteins of Sendai virus.
J. Immunol.
129:2779-2787[Medline].
|
| 34.
|
Pelet, T.,
C. Delenda,
O. Gubbay,
D. Garcin, and D. Kolakofsky.
1996.
Partial characterization of a Sendai virus replication promoter and the rule of six.
Virology
224:405-414[CrossRef][Medline].
|
| 35.
|
Schindler, C.
1998.
STATs as activators of apoptosis.
Trends Cell. Biol.
8:97-98[CrossRef][Medline].
|
| 36.
|
Simon, J. H.,
N. C. Gaddis,
R. A. Fouchier, and M. H. Malim.
1998.
Evidence for a newly discovered cellular anti-HIV-1 phenotype.
Nat. Med.
4:1397-400[CrossRef][Medline].
|
| 37.
|
Stark, G. R.,
I. M. Kerr,
B. R. Williams,
R. H. Silverman, and R. D. Schreiber.
1998.
How cells respond to interferons.
Annu. Rev. Biochem.
67:227-264[CrossRef][Medline].
|
| 38.
|
Tapparel, C.,
S. Hausmann,
T. Pelet,
J. Curran,
D. Kolakofsky, and L. Roux.
1997.
Inhibition of Sendai virus genome replication due to promoter-increased selectivity: a possible role for the accessory C proteins.
J. Virol.
71:9588-9599[Abstract].
|
| 39.
|
Thomas, S. M.,
R. A. Lamb, and R. G. Paterson.
1988.
Two mRNAs that differ by two nontemplated nucleotides encode the amino coterminal proteins P and V of the parmyxovirus SV5.
Cell
54:891-892[CrossRef][Medline].
|
| 40.
| Trono, D. When accessories turn out to be
essential. Nat. Med. 4:1368-1369.
|
| 41.
|
Vidal, S.,
J. Curran, and D. Kolakofsky.
1990.
A stuttering model for paramyxovirus P mRNA editing.
EMBO J.
9:2017-2022[Medline].
|
| 42.
|
Weber, H.,
D. Valenzuela,
G. Luijber,
M. Gubler, and C. Weissmann.
1987.
Single amino acid changes that render human IFN-alpha 2 biologically active on mouse cells.
EMBO J.
6:591-598[Medline].
|
| 43.
|
Yamada, H.,
T. Hayata,
T. Omata-Yamada,
H. Taira,
K. Mizumoto, and K. Iwasaki.
1990.
Association of the Sendai virus C protein with nucleocapsids.
Arch. Virol.
113:245-253[CrossRef][Medline].
|
| 44.
|
Yang, Y. L.,
L. F. Reis,
J. Pavlovic,
A. Aguzzi,
R. Schafer,
A. Kumar,
B. R. Williams,
M. Aguet, and C. Weissmann.
1995.
Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase.
EMBO J.
14:6995-7006.
|
Journal of Virology, August 2001, p. 6800-6807, Vol. 75, No. 15
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.15.6800-6807.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Takeuchi, K., Komatsu, T., Kitagawa, Y., Sada, K., Gotoh, B.
(2008). Sendai Virus C Protein Plays a Role in Restricting PKR Activation by Limiting the Generation of Intracellular Double-Stranded RNA. J. Virol.
82: 10102-10110
[Abstract]
[Full Text]
-
Bartlett, E. J., Cruz, A.-M., Esker, J., Castano, A., Schomacker, H., Surman, S. R., Hennessey, M., Boonyaratanakornkit, J., Pickles, R. J., Collins, P. L., Murphy, B. R., Schmidt, A. C.
(2008). Human Parainfluenza Virus Type 1 C Proteins Are Nonessential Proteins That Inhibit the Host Interferon and Apoptotic Responses and Are Required for Efficient Replication in Nonhuman Primates. J. Virol.
82: 8965-8977
[Abstract]
[Full Text]
-
Randall, R. E., Goodbourn, S.
(2008). Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J. Gen. Virol.
89: 1-47
[Abstract]
[Full Text]
-
Kato, A., Kiyotani, K., Kubota, T., Yoshida, T., Tashiro, M., Nagai, Y.
(2007). Importance of the Anti-Interferon Capacity of Sendai Virus C Protein for Pathogenicity in Mice. J. Virol.
81: 3264-3271
[Abstract]
[Full Text]
-
Ostertag, D., Hoblitzell-Ostertag, T. M., Perrault, J.
(2007). Overproduction of Double-Stranded RNA in Vesicular Stomatitis Virus-Infected Cells Activates a Constitutive Cell-Type-Specific Antiviral Response. J. Virol.
81: 503-513
[Abstract]
[Full Text]
-
Lopez, C. B., Moltedo, B., Alexopoulou, L., Bonifaz, L., Flavell, R. A., Moran, T. M.
(2004). TLR-Independent Induction of Dendritic Cell Maturation and Adaptive Immunity by Negative-Strand RNA Viruses. J. Immunol.
173: 6882-6889
[Abstract]
[Full Text]
-
Garcin, D., Marq, J.-B., Iseni, F., Martin, S., Kolakofsky, D.
(2004). A Short Peptide at the Amino Terminus of the Sendai Virus C Protein Acts as an Independent Element That Induces STAT1 Instability. J. Virol.
78: 8799-8811
[Abstract]
[Full Text]
-
Peeters, B., Verbruggen, P., Nelissen, F., de Leeuw, O.
(2004). The P gene of Newcastle disease virus does not encode an accessory X protein. J. Gen. Virol.
85: 2375-2378
[Abstract]
[Full Text]
-
Kato, A., Cortese-Grogan, C., Moyer, S. A., Sugahara, F., Sakaguchi, T., Kubota, T., Otsuki, N., Kohase, M., Tashiro, M., Nagai, Y.
(2004). Characterization of the Amino Acid Residues of Sendai Virus C Protein That Are Critically Involved in Its Interferon Antagonism and RNA Synthesis Down-Regulation. J. Virol.
78: 7443-7454
[Abstract]
[Full Text]
-
Yoneda, M., Miura, R., Barrett, T., Tsukiyama-Kohara, K., Kai, C.
(2004). Rinderpest Virus Phosphoprotein Gene Is a Major Determinant of Species-Specific Pathogenicity. J. Virol.
78: 6676-6681
[Abstract]
[Full Text]
-
Shaw, M. L., Garcia-Sastre, A., Palese, P., Basler, C. F.
(2004). Nipah Virus V and W Proteins Have a Common STAT1-Binding Domain yet Inhibit STAT1 Activation from the Cytoplasmic and Nuclear Compartments, Respectively. J. Virol.
78: 5633-5641
[Abstract]
[Full Text]
-
de Breyne, S., Monney, R. S., Curran, J.
(2004). Proteolytic Processing and Translation Initiation: TWO INDEPENDENT MECHANISMS FOR THE EXPRESSION OF THE SENDAI VIRUS Y PROTEINS. J. Biol. Chem.
279: 16571-16580
[Abstract]
[Full Text]
-
Strahle, L., Garcin, D., Le Mercier, P., Schlaak, J. F., Kolakofsky, D.
(2003). Sendai Virus Targets Inflammatory Responses, as Well as the Interferon-Induced Antiviral State, in a Multifaceted Manner. J. Virol.
77: 7903-7913
[Abstract]
[Full Text]
-
Gotoh, B., Takeuchi, K., Komatsu, T., Yokoo, J.
(2003). The STAT2 Activation Process Is a Crucial Target of Sendai Virus C Protein for the Blockade of Alpha Interferon Signaling. J. Virol.
77: 3360-3370
[Abstract]
[Full Text]
-
Garcin, D., Marq, J.-B., Goodbourn, S., Kolakofsky, D.
(2003). The Amino-Terminal Extensions of the Longer Sendai Virus C Proteins Modulate pY701-Stat1 and Bulk Stat1 Levels Independently of Interferon Signaling. J. Virol.
77: 2321-2329
[Abstract]
[Full Text]
-
Neumann, G., Whitt, M. A., Kawaoka, Y.
(2002). A decade after the generation of a negative-sense RNA virus from cloned cDNA - what have we learned?. J. Gen. Virol.
83: 2635-2662
[Abstract]
[Full Text]
-
Frolova, E. I., Fayzulin, R. Z., Cook, S. H., Griffin, D. E., Rice, C. M., Frolov, I.
(2002). Roles of Nonstructural Protein nsP2 and Alpha/Beta Interferons in Determining the Outcome of Sindbis Virus Infection. J. Virol.
76: 11254-11264
[Abstract]
[Full Text]
-
Kato, A., Ohnishi, Y., Hishiyama, M., Kohase, M., Saito, S., Tashiro, M., Nagai, Y.
(2002). The Amino-Terminal Half of Sendai Virus C Protein Is Not Responsible for either Counteracting the Antiviral Action of Interferons or Down-Regulating Viral RNA Synthesis. J. Virol.
76: 7114-7124
[Abstract]
[Full Text]
-
Parisien, J.-P., Lau, J. F., Horvath, C. M.
(2002). STAT2 Acts as a Host Range Determinant for Species-Specific Paramyxovirus Interferon Antagonism and Simian Virus 5 Replication. J. Virol.
76: 6435-6441
[Abstract]
[Full Text]
-
Le Mercier, P., Garcin, D., Hausmann, S., Kolakofsky, D.
(2002). Ambisense Sendai Viruses Are Inherently Unstable but Are Useful To Study Viral RNA Synthesis. J. Virol.
76: 5492-5502
[Abstract]
[Full Text]
-
Bossert, B., Conzelmann, K.-K.
(2002). Respiratory Syncytial Virus (RSV) Nonstructural (NS) Proteins as Host Range Determinants: a Chimeric Bovine RSV with NS Genes from Human RSV Is Attenuated in Interferon-Competent Bovine Cells. J. Virol.
76: 4287-4293
[Abstract]
[Full Text]